PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC

The association between disease progression and PD-1/PD-L1 inhibitors in non-small cell lung cancer is unknown.

from Latest articles from Cancer Therapy Advisor News https://ift.tt/2NdlVFw